Previous 10 | Next 10 |
Cassava Sciences may have removed an outlier in the drug group turning a negative result into a positive one, leading to a windfall for its CEO and chief scientific investigator. Cassava Sciences stated mechanisms of action do not explain its results. Simufilam may be a sigma-1 re...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cassava Sciences (NASDAQ: SAVA ) is a clinical-stage biotechnology company trying to fight and cure Alzheimer’s disease. Its laudable mission is “to detect and treat Alzheimer’s disease. ...
Cassava Sciences (SAVA +2.4%) has warned that it may face a clinical hold on its trials for simufilam after the U.S. FDA imposed them this year on two competitors that are also working on Alzheimer's candidates. The notification was tucked away in Cassava's (SAVA +2.7%) 10-K annual report fil...
Cassava Sciences press release (NASDAQ:SAVA): Q4 GAAP EPS of -$0.35 in-line. At December 31, 2021, cash and cash equivalents were $233.4 million, compared to $93.5 million at December 31, 2020, with no debt. For further details see: Cassava Sciences GAAP EPS of -$0.35 in-line
AUSTIN, Texas, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for the year ended December 31, 2021 and provided clinical and business updates. ...
A Citizen Petition submitted to the FDA concerning SAVA's Alzheimer's disease drug was denied, but the subsequent rally in the stock didn't last. This isn't the first time SAVA has failed to produce a sustained rally or sell-off into what appears to be material news. I consider th...
Cassava Sciences, Inc. (SAVA) has been accused of data manipulation on its Alzheimer's therapeutic research by acknowledged short-sellers and scientists. As a pre-clinical company with no proven track record and "meme stock status," it is easy to see that SAVA is a good target for sho...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Since last August, biotech firm Cassava Sciences (NASDAQ: SAVA ) has had a big issue that’s weighed on SAVA stock. Source: Postmodern Studio / Shutterstock.com That would be the citizen petition file...
The FDA has finally responded to the Citizen's Petition filed against Cassava Sciences by the law firm Labaton Sucharow - on behalf of short sellers. The agency won't be taking any action - at least in response to the petition - although it didn't rule out conducting its own investiga...
The FDA's rejection on Thursday of a citizen petition related to Cassava Sciences' (NASDAQ:SAVA) experimental Alzheimer's treatment simufilam has rekindled a long-time debate over how the petitions are being used by some, especially rival companies and those with deep pockets. The abilit...
News, Short Squeeze, Breakout and More Instantly...
Cassava Sciences, Inc. (NASDAQ: SAVA) is one of today's top gainers. The company's shares have moved 24.9% on the day to $12.59. Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 6.6% to $117.99 on volume of 383,510,118 shares Aptevo Therapeutics Inc. (APVO) rose 73.4% to $0.581 on volume of 315,289,581 shares PROSHARES TRUST (SQQQ) rose 8.7% to $8.11 on volume of 173,682,364 sha...
A look at the top 10 most actives in the United States Aptevo Therapeutics Inc. (APVO) rose 45.1% to $0.486 on volume of 64,992,551 shares Verb Technology Company Inc. (VERB) rose 3.5% to $0.1205 on volume of 54,410,242 shares NVIDIA Corporation (NVDA) fell 4.4% to $120.752 on volume of 4...